Article
Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors.
Med (New York, N.Y.) - 13 Jun 2025
Möhrmann Lino, Rostock Lysann, Werner Maximilian, Oleś Małgorzata, Arnold Jonas S, Paramasivam Nagarajan, Jöhrens Korinna, Rupp Luise, Schmitz Marc, Richter Daniela, Uhrig Sebastian, Fröhlich Martina, Hutter Barbara, Hüllein Jennifer, Jahn Arne, Arlt Marie, Möhrmann Elena E, Hanf Dorothea, Gieldon Laura, Kreutzfeldt Simon, Heilig Christoph E, Teleanu Maria-Veronica, Lipka Daniel B, Beck Katja, Baude-Müller Annika, Mock Andreas, Jelas Ivan, Rieke Damian T, Wiesweg Marcel, Brandts Christian, Boerries Melanie, Illert Anna L, Desuki Alexander, Kindler Thomas, Krackhardt Angela M, Westphalen C Benedikt, Christopoulos Petros, Apostolidis Leonidas, Stenzinger Albrecht, Allgäuer Michael, Neumann Olaf, Kerle Irina A, Horak Peter, Heining Christoph, Grosch Heidrun, Schröck Evelin, Hübschmann Daniel, Fröhling Stefan, Glimm Hanno
Abstract excerpt
BACKGROUND: Thymic epithelial tumors (TETs) are rare malignancies with limited treatment options and underexplored molecular features. METHODS: We examined the genomic landscape and therapeutic outcomes in 81 patients with advanced TETs, including thymic carcinomas (TCs), thymomas, and thymic neuroendocrine neoplasms (TNENs), who were enrolled in the MASTER trial, a prospective observational precision oncology...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.